NEW YORK, NY / ACCESSWIRE / March 7, 2018 / TGV Therapeutics, the pharmaceutical company developing first-in-class drugs for fighting antibiotic-resistant infections, announced today it is working with the National Institutes of Health to expand its research on a drug that shows promise against new fungal superbugs.
TGV Therapeutics and its advisors, Dr. George and Victor Tetz, said initial data indicate their drug candidate, MYC-053, is effective against numerous emerging multidrug-resistant invasive fungal pathogens, including recent emerging threat – Candida auris, which appears to spread in healthcare facilities. The overall crude in-hospital mortality rate of C.auris candidemia ranges from 30% to 60% and today it is one of the deadiest fungi. Anne Schuchat, former acting director of the CDC, has formed it a “catastrophical threat”.
MYC-053 is a structurally distinct both oral and IV antifungal antibiotic with a unique dual mode of action that shows promise in fighting a number of pathogenic fungi. After reviewing TGV’s application to conduct studies, the NIH connected the company with the number of research centers for expanded in-depth research.
“We are pleased that the NIH recognizes the potential of MYC-053 and the urgent need for expanded research and development of this groundbreaking drug,” said Haran Schlamm, a member of the scientific advisory board. “As we have seen with antibiotics, some strains of fungus are becoming increasingly resistant to the antifungal agents. And it is crucial we speed up research and testing of this drug to fight existing emerging multidrug-resistant species, as well as to avoid the spread of another dangerous fungi.”
TGV Therapeutics is a biopharmaceutical company committed to and developing novel antifungal antibiotics that will bring therapy of invasive fungal infections to a principally new level of effectiveness. TGV Therapeutics’ ultimate goal is to apply the MYC-053 to some of the deadliest fungal infections – those caused by multiresistant Candida species, including Candida glabrata and Candida auris.
For more information about Victor and George Tetz and TGV Therapeutics, please contact Irene Johnson at (917) 477-7881, Email: Irene@thronepr.com
SOURCE: TGV Therapeutics
- Data indicates that the antibiotic MYC-053; developed by TGV Therapeutics, has proven effective against the deadly fungal infection Candida auris (C.auris) candidemia.
- Initial testing by TGV was so promising the NIH decided to expand research into MYC-053.
- C.auris is a pathogenic fungus that has been known to spread in healthcare facilities. C.auris can infect wounds, the bloodstream, and the urinary tract.
- The pathogen is extremely dangerous because itis resistant to many existing antifungal drugs.
- MYC-053 is TGV’s lead product candidate, and itis described as a “novel antifungal agent that is structurally distinct fromthe three main classes of antifungal antibiotics.”.
Mycobactovir for the Treatment of Vulvovaginal Candidiasis: Results from A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial (ex-US)
TGV-Laboratories to Present Results from Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial. Research Presented in a Poster Session at American Society for Microbiology (ASM) Microbe 2018
NEW YORK, NY, June 10, 2018 — TGV-Therapeutics (TGV), a privately held company and our goal is to bring the therapy of invasive fungal infections to a principally new level of the efficacy. The study, coordinated by Drs. V. Tetz and G. Tetz, was presented by Dr. G. Tetz in a poster session at American Society for Microbiology (ASM) Microbe 2018, June 7–11, 2018, in Atlanta